Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

NCT01442038 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2651

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Artery Disease
Angina Pectoris

Interventions

DRUG: Ranolazine
DRUG: Placebo

Sponsor

Gilead Sciences